Literature DB >> 18806241

Successful treatment of hallucinations associated with sensory impairment using gabapentin.

Suzanne Holroyd1, Samia Sabeen.   

Abstract

Sensory impairment hallucinations, such as visual hallucinations with visual loss, may not respond to traditional treatments such as antipsychotics. In this case series, the authors describe four patients with either visual or musical hallucinations associated with sensory impairment who were successfully treated with gabapentin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806241     DOI: 10.1176/jnp.2008.20.3.364

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  5 in total

1.  Cases: Charles Bonnet syndrome: visual loss and hallucinations.

Authors:  M L Jackson; Joseph Ferencz
Journal:  CMAJ       Date:  2009-08-04       Impact factor: 8.262

Review 2.  Musical hallucinations: review of treatment effects.

Authors:  Jan A F Coebergh; R F Lauw; R Bots; I E C Sommer; J D Blom
Journal:  Front Psychol       Date:  2015-06-16

3.  Musical hallucinations - a challenge for psychiatric therapeutical management. Case report.

Authors:  B E Focseneanu; G Marian
Journal:  J Med Life       Date:  2015 Oct-Dec

Review 4.  Hallucinations Experienced by Visually Impaired: Charles Bonnet Syndrome.

Authors:  Linda Pang
Journal:  Optom Vis Sci       Date:  2016-12       Impact factor: 1.973

Review 5.  Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management.

Authors:  John O'Brien; John Paul Taylor; Clive Ballard; Roger A Barker; Clare Bradley; Alistair Burns; Daniel Collerton; Sonali Dave; Rob Dudley; Paul Francis; Andrea Gibbons; Kate Harris; Vanessa Lawrence; Iracema Leroi; Ian McKeith; Michel Michaelides; Chaitali Naik; Claire O'Callaghan; Kirsty Olsen; Marco Onofrj; Rebecca Pinto; Gregor Russell; Peter Swann; Alan Thomas; Prabitha Urwyler; Rimona Sharon Weil; Dominic Ffytche
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-25       Impact factor: 10.154

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.